Datos de fase III de olatorepatida --agonista dual sesgado de GLP-1/GIP de Hansoh-- presentados en la EASD
- Pérdida de peso del 19,3 % en la semana 48: datos de fase III de olatorepatida —agonista dual sesgado de GLP-1/GIP de Hansoh— presentados en la EASD MILÁN, 2 de octubre de 2026 /PRNewswire/ -- Del 28 de septiembre al 2 de octubre de 2026 se celebra en Milán (Italia) la reunión anual de...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Xryma Plc - Dimisión de consejeros independientes no ejecutivos
- TPRA Media - Aligned with UAE AI Strategy 2031: Credibility Engineering for a Machine-Readable Nation
- Starlink Satellite-to-Mobile Service in Kasachstan gestartet
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →